Maqola

Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial

Gus GazzardNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Ophthalmology, University College London, London, UK. Electronic address: [email protected]Evgenia KonstantakopoulouNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Ophthalmology, University College London, London, UKDavid F. Garway‐HeathNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Ophthalmology, University College London, London, UKAnurag GargNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Ophthalmology, University College London, London, UKVictoria VickerstaffMarie Curie Palliative Care Research Department, UCL Division of Psychiatry, University College London, London, UK; The Research Department of Primary Care and Population Health, University College London, London, UKRachael HunterThe Research Department of Primary Care and Population Health, University College London, London, UKGareth AmblerDepartment of Statistical Science, University College London, London, UKCatey BunceNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UK; School of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UKRichard WormaldNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Ophthalmology, University College London, London, UK; London School of Hygiene & Tropical Medicine, London, UKNeil NathwaniNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UKKeith BartonNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UKGary S. RubinInstitute of Ophthalmology, University College London, London, UKMarta BuszewiczThe Research Department of Primary Care and Population Health, University College London, London, UKRupert BourneDepartment of Statistical Science (G Ambler PhD), University College London, London, UK;David C. BroadwayNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UKAmanda DavisNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UKHari JayaramDepartment of Statistical Science (G Ambler PhD), University College London, London, UK;Yuzhen JiangSchool of Population Health and Environmental Sciences,Sheng Yang LimThe Research Department of Primary Care and Population Health (Joanna LiputThe Research Department of Primary Care and Population Health (T D MannersPalliative Care Research Department, UCL Division of Psychiatry (V Vickerstaff MSc),Stephen MorrisSchool of Population Health and Environmental Sciences,Nicholas G. StrouthidisC Bunce); and London School of Hygiene & Tropical Medicine, London, UKSarah WilsonFaculty of Life Sciences and Medicine, King's College London, London, UK (Haogang ZhuC Bunce); and London School of Hygiene & Tropical Medicine, London, UK

2019en

ABI

Annotatsiya

BACKGROUND: Primary open angle glaucoma and ocular hypertension are habitually treated with eye drops that lower intraocular pressure. Selective laser trabeculoplasty is a safe alternative but is rarely used as first-line treatment. We compared the two. METHODS: In this observer-masked, randomised controlled trial treatment-naive patients with open angle glaucoma or ocular hypertension and no ocular comorbidities were recruited between 2012 and 2014 at six UK hospitals. They were randomly allocated (web-based randomisation) to initial selective laser trabeculoplasty or to eye drops. An objective target intraocular pressure was set according to glaucoma severity. The primary outcome was health-related quality of life (HRQoL) at 3 years (assessed by EQ-5D). Secondary outcomes were cost and cost-effectiveness, disease-specific HRQoL, clinical effectiveness, and safety. Analysis was by intention to treat. This study is registered at controlled-trials.com (ISRCTN32038223). FINDINGS: Of 718 patients enrolled, 356 were randomised to the selective laser trabeculoplasty and 362 to the eye drops group. 652 (91%) returned the primary outcome questionnaire at 36 months. Average EQ-5D score was 0·89 (SD 0·18) in the selective laser trabeculoplasty group versus 0·90 (SD 0·16) in the eye drops group, with no significant difference (difference 0·01, 95% CI -0·01 to 0·03; p=0·23). At 36 months, 74·2% (95% CI 69·3-78·6) of patients in the selective laser trabeculoplasty group required no drops to maintain intraocular pressure at target. Eyes of patients in the selective laser trabeculoplasty group were within target intracoluar pressure at more visits (93·0%) than in the eye drops group (91·3%), with glaucoma surgery to lower intraocular pressure required in none versus 11 patients. Over 36 months, from an ophthalmology cost perspective, there was a 97% probability of selective laser trabeculoplasty as first treatment being more cost-effective than eye drops first at a willingness to pay of £20 000 per quality-adjusted life-year gained. INTERPRETATION: Selective laser trabeculoplasty should be offered as a first-line treatment for open angle glaucoma and ocular hypertension, supporting a change in clinical practice. FUNDING: National Institute for Health Research, Health and Technology Assessment Programme.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.1016/s0140-6736(18)32213-x

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar